A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

This publication has 20 references indexed in Scilit:

• Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2007
• Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272
  Cancer Research, 2006
• Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
  Proceedings of the National Academy of Sciences, 2006
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
  The Lancet, 2005
• Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2005
• Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2004
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
  Cancer Research, 2004
• FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
  The Oncologist, 2003
• Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2003
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000